##STR00001##

Disclosed is a method for preparing compound Formula S-1, comprising resolving compound Formula rac-2 with a compound of Formula 3 wherein R.sup.1.Math.R.sup.4, m and n are as defined in the disclosure.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

##STR00001##

Disclosed is a method for preparing compound S-1 (S-1) comprising resolving compound rac-2 (rac-2) with a compound of Formula 3 wherein R.sup.1, R.sup.4, m and n are as defined in the disclosure.

##STR00001##

Disclosed is a method for preparing compound S-1 (S-1) comprising resolving compound rac-2 (rac-2) with a compound of Formula 3 wherein R.sup.1, R.sup.4, m and n are as defined in the disclosure.

##STR00001##

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

A method for making thermosetting polyimides from resveratrol including converting resveratrol to trisaniline, reacting trisaniline with one or more dianhydride and thermosetting endcap to form amic acid, thermally imidizing amic acid to form polyimide oligomer, and cross-linking polyimide oligomer with heat and pressure to generate polyimide thermoset.

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.